The evolving role of bisphosphonates

Seminars in Oncology

Volumn 28, Issue 3, 2001, Pages 284-290

  Theriault, Richard L ^a   Hortobagyi, Gabriel N ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE CANCER; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPERCALCEMIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034984504     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90121-6     Document Type: Article

References (49)

1. The abdominal visceral innervation and the emetic reflex: Pathways, pharmacology, and plasticity
2. Neuropharmacology of chemotherapy-induced emesis
3. Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia
4. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence based, clinical practice guidelines
5. Current role of protective agents in cancer treatment
6. Clinical needs for hematopoietic growth factors: Old and new
7. Update of recommendatikons for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
8. Colony-stimulating factors: Current applications and perspectives
9. Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia
10. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer
11. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
12. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study
13. Recombinant human erythropoietin in the treatment of cancer-related anemia
14. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo
15. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo
16. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats
17. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin
18. Alendronate treatment of the postmenopausal osteoporotic women: Effect of multiple dosages on bone mass and bone remodeling
19. Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease
20. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
21. Metabolism of dosodium ethane-1-hydroxy-1,1,-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey
22. Uptake of bone my pyrophosphate, diphosphonates and their technetium derivatives
23. Aledronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemic models
24. Retention of etidronate in human, dog and rat
25. Dose-response in the treatment of hypercalmecia of malignancy by a single infusion of the bisphosphonate AHPrBP
26. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg doses
27. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
28. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone lesions
29. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy
30. Clinical research update zoledronate
31. Parathyroid hormone and PTH-like protein stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin- 6 in osteoclastogenesis
32. Polypeptide growth factors in bone matrix
33. Role of TGF β in bone remodeling
34. Treatment of skeletal disease in breast cancer: A controlled clodronate trial
35. Treatment of skeletal disease in breast cancer with clodronate
36. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients
37. Efficacy of pamidronate in breast cancer with bone metastases: A randomized double-blind placebo controlled multicenter study
38. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: A randomized, placebo-controlled trial
39. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
40. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
41. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
42. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
43. Markers of bone resorption in patients treated with pamidronate
44. Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model
45. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
46. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
47. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
48. Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats
49. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment